Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to ...